Cethromycin

...Japan. Advanced Life said it will retain exclusive rights to cethromycin in the rest of the world, including North America and Europe and excluding Japan, where Abbott Laboratories <ABT.N> retains rights to the drug. The overall...

In this article: Wyeth, Antibiotic, Abbott Laboratories, Nasdaq, Japan, and North America

...for cethromycin in the Asia Pacific region excluding Japan. Cethromycin is a novel once-a-day oral antibiotic for the treatment of community respiratory tract infections. Advanced Life Sciences will retain exclusive rights to cethromycin...

In this article: Wyeth, Antibiotic, Macrolide, Streptococcus pneumoniae, Revenue, and Haemophilus influenzae

...and respiratory disease. The Company's most advanced product candidate, Cethromycin, is a novel once-a-day oral antibiotic that completed two pivotal phase III clinical trials in community acquired pneumonia. The Company has an exclusive...

In this article: Antibiotic, Respiratory disease, FDA, Abbott Laboratories, GlaxoSmithKline plc, Sanofi-Aventis, Pfizer Inc., and Merck & Co.

Cethromycin was the most active antibiotic tested in this study. ... (Aventis Pharma Co., Tokyo, Japan) and cethromycin (Dainabbott Labor- atories, Osaka, Japan) ...

... Sciences and Wyeth Sign Commercialization Agreement for Cethromycin in Asia Pacific Region (HSMN NewsFeed: Medical ... to cethromycin in Japan. Forward ...

... agreement for cethromycin in the Asia Pacific region excluding Japan. ... ( 1) Abbott Laboratories retains rights to cethromycin in Japan. ...

Read the Advanced Life Sciences Holdings, Inc. ADLS.OB company profile at ... agreement with Wyeth for cethromycin in the Asia Pacific region excluding Japan. ...

... respiratory tract infections, in the Asia-Pacific region, excluding Japan. ALS will retain exclusive rights to cethromycin in the rest of the world, ...

... agreement for cethromycin in the Asia Pacific region excluding Japan. ... to cethromycin under an exclusive worldwide license (except in Japan) from Abbott ...